🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against increasingly resistant strains of the infection, according to health experts.

A Worldwide Public Health Issue

The sexually transmitted infection are escalating worldwide, with estimates suggesting more than 82 million infections each year. Notably increased rates are seen in Africa and countries within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have hit a all-time high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The clearance of new treatments for gonorrhoea is an important and timely advancement in the context of rising global incidence, escalating drug resistance and the very limited available drugs currently available.”

Public health authorities are deeply concerned about the surge in drug-resistant strains. The World Health Organization has listed it as a "critical concern". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Secure Approval

One new antibiotic, also known as a brand name, was approved by the US Food and Drug Administration in mid-December for use against gonorrhoea. This infection can lead to significant complications, including infertility. Researchers anticipate that focused deployment of this new drug will help slow the spread of drug resistance.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, gained clearance in concurrent days. This medication, which is additionally indicated for urinary tract infections, was demonstrated in studies to be able to combat superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP worked alongside the pharmaceutical company its industry partner to develop it.

“This authorization represents a significant shift in the management of highly resistant gonorrhoea, which until now has been staying ahead of our drug pipeline.”

Research Study Results and Worldwide Availability

Based on data released by a major medical journal, zoliflodacin eradicated more than 90% of genital gonorrhoea infections. This puts it on an similar efficacy with the typical regimen, which combines two antibiotics. The study included nearly 1,000 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the authority to register and commercialise the drug in many low-income and middle-income countries.

Medical professionals on the front lines have expressed positive views. Having a single-dose, oral treatment like this is described as a "game-changer" for gonorrhoea control. This is considered crucial to reduce the burden of the illness for people and to stop the proliferation of extremely resistant gonorrhoea globally.